Clinical trial shows benefit of new approach for metastatic breast cancer

March 26, 2014

Drs. Mark Clemons and Christina Addison have just published a study examining the effectiveness of using drugs called bisphosphonates, which reduce pain and skeletal complications in patients whose breast cancer has spread to the bone. This Canadian Breast Cancer Foundation-funded clinical trial involved 71 eligible patients from Ottawa and showed that patients could be safely treated every 3 months instead of every month as is the current standard. The benefits for these women suffering from breast cancer included fewer treatments, fewer trips to the cancer centre and less toxicity. This approach also resulted in direct and indirect cost savings for the health-care system. You can read the full study in Breast Cancer Research and Treatment.

Funders: Canadian Breast Cancer Foundation and Government of Ontario

About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.

Media contact
Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
613-737-8899 x73687
613-323-5680 (cell)